Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).

OBJECTIVES To describe raltegravir pharmacokinetics at steady-state in HIV/hepatitis C virus (HCV)-coinfected patients under antiretroviral (ARV) treatment with (n = 5) and without (n = 5) advanced liver cirrhosis (Child-Pugh C). METHODS This was a non-randomized, Phase I, parallel-assignment, open-label pharmacokinetic study in HIV/HCV-coinfected patients with Child-Pugh grade C hepatic cirrhosis. We recruited clinically stable HIV/HCV-coinfected adult patients with controlled HIV viraemia (<50 copies/mL) for at least 6 months. Raltegravir (400 mg twice daily) was added under fasting conditions for 5 days to the successful ritonavir-boosted protease inhibitor-based ARV regimen. The trial was registered in the ClinicalTrials.gov database (NCT01289951) (LIVERAL). RESULTS Raltegravir AUC0-12 and C12 were increased 1.72-fold (90% CI, 1.02 to 2.92) and 6.58-fold (90% CI, 2.92 to14.85), respectively, in patients with advanced liver cirrhosis. No safety issues were identified and raltegravir was well tolerated by all patients. CONCLUSIONS Raltegravir plasma levels are increased in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). Despite the higher exposure, raltegravir was safe and well tolerated.

[1]  C. Quereda,et al.  Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. , 2012, Journal of acquired immune deficiency syndromes.

[2]  R. Leavitt,et al.  Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfection , 2012, HIV medicine.

[3]  C. Quereda,et al.  Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage. , 2010, AIDS.

[4]  C. Viscoli,et al.  Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. , 2009, The Journal of antimicrobial chemotherapy.

[5]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[6]  B. Clotet,et al.  Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment , 2009, Antimicrobial Agents and Chemotherapy.

[7]  F. Conti,et al.  Safety and Efficacy of Raltegravir in HIV‐Infected Transplant Patients Cotreated with Immunosuppressive Drugs , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  J. Wagner,et al.  Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics , 2009, Antimicrobial Agents and Chemotherapy.

[9]  D. Hazuda,et al.  Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[10]  J. Poirier,et al.  Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  C. Cooper.  An Overview of HIV and Chronic Viral Hepatitis Co-Infection , 2008, Digestive Diseases and Sciences.

[12]  C. Quereda,et al.  Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. , 2008, AIDS.

[13]  P. Lu,et al.  Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation , 2008, Journal of clinical pharmacology.

[14]  I. Mcintosh,et al.  Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme , 2007, Drug Metabolism and Disposition.

[15]  V. Soriano,et al.  Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. , 2007, The Journal of infectious diseases.

[16]  V. Soriano,et al.  Liver cirrhosis in HIV‐infected patients: prevalence, aetiology and clinical outcome , 2007, Journal of viral hepatitis.

[17]  M. Sulkowski,et al.  Therapeutic issues in HIV/HCV-coinfected patients , 2007, Journal of viral hepatitis.

[18]  C. Katlama,et al.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.

[19]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[20]  C. Quereda,et al.  Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. Aarnoutse,et al.  Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. , 2003, Journal of acquired immune deficiency syndromes.

[22]  C. Funck-Brentano,et al.  Effect of interferon α‐ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N‐acetyltransferase‐2 activities in patients with chronic active hepatitis C , 2002, Clinical pharmacology and therapeutics.

[23]  P. Arns,et al.  Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6 , 1998, Clinical pharmacology and therapy.

[24]  K. Byth,et al.  Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. , 1995, Biochemical pharmacology.

[25]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.